Home › Neuroblastoma
Neuroblastoma clinical trials recruiting in the U.S.
47 studies for Neuroblastoma are recruiting participants at sites across the United States.
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
Cities with the most studies
- Boston, MA13 studies
- Washington, DC11 studies
- New York City, NY10 studies
- Dallas, TX9 studies
- St. Louis, MO9 studies
- Philadelphia, PA9 studies
- Memphis, TN9 studies
- Birmingham, AL8 studies
- Minneapolis, MN8 studies
- Hartford, CT8 studies
- Aurora, CO8 studies
- Houston, TX7 studies
- Orlando, FL7 studies
- Miami, FL7 studies
- Los Angeles, CA7 studies
- San Francisco, CA7 studies
- Atlanta, GA7 studies
- Cincinnati, OH7 studies
- Portland, OR6 studies
- Harrisburg, PA6 studies
- Honolulu, HI6 studies
- Little Rock, AR6 studies
- Durham, NC6 studies
- Gainesville, FL6 studies
- Salt Lake City, UT6 studies
- Greenburgh, NY6 studies
- Chicago, IL6 studies
- Seattle, WA6 studies
- San Diego, CA5 studies
- Oakland, CA5 studies
- Austin, TX5 studies
- Mountain View, CA5 studies
- Nashville, TN5 studies
- Ann Arbor, MI5 studies
- Columbus, OH5 studies
- Charlotte, NC4 studies
- Charleston, SC4 studies
- Grand Rapids, MI4 studies
- Louisville, KY4 studies
- Clifton, NJ4 studies
By state
- Alabama8 studies
- Arizona3 studies
- Arkansas6 studies
- California14 studies
- Colorado8 studies
- Connecticut9 studies
- District of Columbia6 studies
- Florida9 studies
- Georgia9 studies
- Hawaii6 studies
- Illinois6 studies
- Indiana3 studies
- Iowa3 studies
- Kentucky5 studies
- Maryland8 studies
- Massachusetts13 studies
- Michigan8 studies
- Minnesota9 studies
- Missouri10 studies
- New Jersey6 studies
- New York13 studies
- North Carolina7 studies
- North Dakota3 studies
- Ohio8 studies
- Oregon6 studies
- Pennsylvania14 studies
- Rhode Island3 studies
- South Carolina4 studies
- South Dakota3 studies
- Tennessee12 studies
- Texas15 studies
- Utah6 studies
- Virginia3 studies
- Washington6 studies
- Wisconsin4 studies
Recently updated studies
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Sep 28, 2026 · NCT01109394Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Sep 24, 2026 · NCT06995872Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
Up to age 30 · All sexes · Updated Sep 24, 2026 · NCT06172296Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
RecruitingObservational study
Ages 4 and older · All sexes · Updated Sep 22, 2026 · NCT01005654Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Biomarkers of Resiliency In Childhood Cancer Surgery
RecruitingObservational study
Ages 3 to 25 · All sexes · Updated Sep 14, 2026 · NCT06674811Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262B7-H3.CD28Z.CART in Solid Tumors
RecruitingPhase 1
9 Months – 30 Years · All sexes · Updated Sep 3, 2026 · NCT07358260Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RecruitingPhase 2
Ages 1 to 21 · All sexes · Updated Sep 3, 2026 · NCT06540963International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
RecruitingObservational study
All ages · All sexes · Updated Sep 3, 2026 · NCT03088020N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RecruitingPhase 2
18 Months – 19 Years · All sexes · Updated Aug 28, 2026 · NCT06528496Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
RecruitingPhase 2
Ages 1 to 39 · All sexes · Updated Aug 24, 2026 · NCT07635056Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RecruitingPhase 2Healthy volunteers welcome
All ages · All sexes · Updated Aug 11, 2026 · NCT04936529SPEARHEAD-3 Pediatric Study
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
RecruitingPhase 2
All ages · All sexes · Updated Jul 28, 2026 · NCT06057948PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
RecruitingPhase 1
Ages 1 to 24 · All sexes · Updated Jul 21, 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
RecruitingPhase 2
Ages 1 to 31 · All sexes · Updated Jul 20, 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jul 14, 2026 · NCT07027748From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.